Loading
Wisconsin life-science company whose OncoMate test for microsatellite instability is an FDA companion diagnostic for pembrolizumab.
Promega Corporation, the applicant on FDA records at Madison, Wisconsin, makes the OncoMate MSI Dx Analysis System, approved in November 2025 as the companion diagnostic for pembrolizumab with lenvatinib in microsatellite-stable endometrial carcinoma and in September 2026 for pembrolizumab in MSI-high solid tumours.
Promega's microsatellite instability test, approved twice: to find microsatellite-stable endometrial cancer for pembrolizumab with lenvatinib, and MSI-high solid tumours for pembrolizumab.
Shares Companion diagnostics, Endometrial cancer.
Shares Companion diagnostics, Endometrial cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/